KFRC

Business Context and Reporting Period

Kforce Inc. filed its Form 10-Q for the quarterly period ended March 31, 2002. The company operates in three functional service segments: Information Technology, Finance and Accounting, and Health and Life Sciences. The filing reflects a challenging economic environment, particularly impacting the Information Technology and Finance segments, alongside significant accounting policy changes regarding revenue recognition and goodwill amortization.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net service revenues decreased 32.6% year-over-year. This was driven by a 25.6% drop in Flexible Billings (primarily due to a 40.9% decline in IT billings) and a 66.7% collapse in Search Fees.
• Profitability Shift: The company swung from a net income of $2.8 million in Q1 2001 to a net loss of $1.6 million in Q1 2002. Operating loss was $2.0 million.
• Margin Compression: Gross margin fell to 33.2% from 41.0%, attributed to a lower mix of high-margin Search Services and an increase in lower-margin Health and Life Sciences flexible billings.
• Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 38.5% to $43.1 million, aided by reduced commissions and operational streamlining.
• Accounting Changes:
  • Goodwill: Effective Jan 1, 2002, the company adopted SFAS 142, discontinuing goodwill amortization. This reduced depreciation/amortization expense by approximately $1.0 million compared to the prior year.
  • Revenue Recognition: Billable expenses were reclassified from direct costs to revenue, increasing reported revenue by $2.8 million for the quarter.

Guidance, Outlook, and Risks

• Liquidity Position: As of March 31, 2002, the company held $1.3 million in cash and had $26.0 million outstanding on a $90 million credit facility. Available capacity was approximately $18.8 million.
• Covenant Compliance Risk: The company noted it would not be in compliance with certain financial covenants (specifically EBITDA targets) if it borrowed sufficient funds to trigger them. Management stated they are currently not in compliance with these covenants if applicable, though no default has been declared.
• Goodwill Impairment: The company is conducting its initial transitional goodwill impairment test. Management warned that potential impairment could range from nominal to exceeding the majority of existing goodwill ($95.6 million).
• Capital Allocation: The Board authorized a stock repurchase program of up to $115 million. As of May 14, 2002, approximately $17.7 million remained available under this authorization, subject to credit facility limitations.
• Outlook: Management believes cash flow from operations and borrowings will meet working capital needs for the next 12 months, but warned that further deterioration in market conditions could negatively impact results.

Investor Verification Checklist

• Covenant Status: Verify the specific terms of the credit facility covenants and the company's current EBITDA performance to assess the risk of a technical default.
• Goodwill Impairment Test: Monitor the results of the SFAS 142 transitional goodwill impairment test, as a significant write-down could materially impact equity.
• Segment Mix: Analyze the sustainability of the shift toward Health and Life Sciences revenue versus the continued decline in Information Technology and Finance segments.
• Cash Burn vs. Repurchases: Evaluate the impact of the ongoing stock repurchase program on liquidity given the reduced operating cash flow and existing debt levels.
• Receivables Quality: Review the allowance for doubtful accounts and fallouts ($6.8 million) given the economic downturn and potential for increased client defaults.